Yu Jie, He Xinyun, Fang Chunju, Wu Haixia, Hu Lei, Xue Yingbo
Department of Oncology, Guizhou Provincial People's Hospital, Guiyang, Guizhou 550001, P.R. China.
Department of Laboratory Medicine, Guizhou Women's and Children's Hospital, Guiyang, Guizhou 550003, P.R. China.
Exp Ther Med. 2022 Apr;23(4):281. doi: 10.3892/etm.2022.11210. Epub 2022 Feb 15.
Lung cancer is one of the main threats to human health. Survival of patients with lung cancer depends on timely detection and diagnosis. Among the genetic irregularities that control cancer development and progression, there are microRNAs (miRNAs/miRs). The present study aimed to investigate the expression patterns of miR-200a-3p and transcription factor GATA-6 (GATA6) in peripheral blood of patients with non-small cell lung cancer (NSCLC) and their clinical significance. The expression patterns of miR-200a-3p and GATA6 in the peripheral blood of patients with NSCLC and healthy subjects were measured via reverse transcription-quantitative PCR. The correlation between GATA6/miR-200a-3p expression and their diagnostic efficacy were analyzed by receiver operating characteristic curve analysis. The association between miR-200a-3p/GATA6 expression with the patient clinicopathological characteristics, and their correlation with carcinoembryonic antigen (CEA), neuron specific enolase (NSE) and squamous cell carcinoma antigen (SCCAg) were evaluated. The cumulative survival rate was examined, and whether miR-200a-3p and GATA6 expression levels were independently correlated with the prognosis of NSCLC was analyzed using multivariate logistic regression model. The results demonstrated that the expression of miR-200a-3p was high and that of GATA6 was low in the peripheral blood of patients with NSCLC, and both exhibited high clinical diagnostic efficacy. miR-200a-3p was revealed to target GATA6 by dual-luciferase assay. miR-200a-3p in the peripheral blood was correlated with TNM stage, lymph node metastasis and distal metastasis, while GATA6 in the peripheral blood was correlated with TNM stage and lymph node metastasis. miR-200a-3p and GATA6 were positively correlated with CEA and SCCAg, but not with NSE. High expression of miR-200a-3p and low expression of GATA6 predicted poor prognosis in patients with NSCLC. After adjusting for TNM stage, lymph node metastasis, distance metastasis, GATA6, CEA, NSE and SCCAg in the logistic regression model, it was indicated that the high expression of miR-200a-3p increased the risk of death in patients with NSCLC. Collectively, it was revealed that miR-200a-3p and GATA6 were abnormally expressed in the peripheral blood of patients with NSCLC. Serum levels of miR-200a-3p >1.475 and GATA6 <1.195 may assist the early diagnosis of NSCLC. GATA6 may function in NSCLC as a miR-200a-3p target, which may provide a future reference for NSCLC early diagnosis and treatment.
肺癌是对人类健康的主要威胁之一。肺癌患者的生存取决于及时的检测和诊断。在控制癌症发展和进展的基因异常中，存在微小RNA（miRNA/miR）。本研究旨在探讨非小细胞肺癌（NSCLC）患者外周血中miR-200a-3p和转录因子GATA-6（GATA6）的表达模式及其临床意义。通过逆转录定量PCR检测NSCLC患者和健康受试者外周血中miR-200a-3p和GATA6的表达模式。通过受试者工作特征曲线分析GATA6/miR-200a-3p表达与其诊断效能之间的相关性。评估miR-200a-3p/GATA6表达与患者临床病理特征之间的关联，以及它们与癌胚抗原（CEA）、神经元特异性烯醇化酶（NSE）和鳞状细胞癌抗原（SCCAg）的相关性。检查累积生存率，并使用多变量逻辑回归模型分析miR-200a-3p和GATA6表达水平是否与NSCLC的预后独立相关。结果表明，NSCLC患者外周血中miR-200a-3p表达高而GATA6表达低，两者均具有较高的临床诊断效能。双荧光素酶测定显示miR-200a-3p靶向GATA6。外周血中的miR-200a-3p与TNM分期、淋巴结转移和远处转移相关，而外周血中的GATA6与TNM分期和淋巴结转移相关。miR-200a-3p和GATA6与CEA和SCCAg呈正相关，但与NSE无关。miR-200a-3p高表达和GATA6低表达预示NSCLC患者预后不良。在逻辑回归模型中调整TNM分期、淋巴结转移、远处转移、GATA6、CEA、NSE和SCCAg后，表明miR-200a-3p高表达增加了NSCLC患者的死亡风险。总体而言，揭示了miR-200a-3p和GATA6在NSCLC患者外周血中异常表达。血清miR-200a-3p>1.475和GATA6<1.195水平可能有助于NSCLC的早期诊断。GATA6可能作为miR-200a-3p的靶点在NSCLC中发挥作用，这可能为NSCLC的早期诊断和治疗提供未来参考。
